Winton Matthew

CervoMed CCO Winton Matthew bought 5,000 shares ($41.4K) in 2 transactions at $8.43 and $7.95 on Nov 17–18, with 3 other insiders buying within 14 days

Winton Matthew, Chief Commercial and Business at CervoMed (CRVO), executed 2 separate purchases totaling 5,000 shares ($41.4K) at an average of $8.29, increasing his holdings by 50.0% from 10,000 to 15,000 shares. The purchases occurred on November 17–18 at prices below the current market price of $8.62, and notably, 3 other insiders also bought within the past 14 days, forming a cluster pattern. CervoMed remains unprofitable on a full-year basis with net income of $-7.7M but shows recent revenue growth of 36.3% on a quarterly revenue of $322.6K; the stock is currently trading 39.7% below its 52-week high of $14.29. This cluster activity from multiple insiders at a small-cap, unprofitable company signals shared internal perspective on valuation or opportunity, though the company's negative earnings and early-stage revenue profile warrant deep review.

Chief Commercial Officer Winton Matthew buys 10,000 shares of CRVO at $7.57; cluster pattern with 3 others in 14 days

Winton Matthew, Chief Commercial and Business officer, purchased 10,000 shares at $7.57 on 2025-11-14, establishing an initial position. The transaction is part of a broader cluster pattern in which 3 other insiders also bought within the past 14 days, suggesting coordinated or contextually-aligned acquisition activity. However, the company is unprofitable with net income of $-7.7M in the latest fiscal year, though it shows annual revenue growth of +36.3%, and the stock currently trades at $8.21, down -42.6% from its 52-week high of $14.29. The insider's cross-ticker track record consists of only 1 prior buy, limiting inference about pattern consistency. Investors should monitor whether this multi-insider buying aligns with strategic fundamentals or represents conviction in a turnaround trajectory at an unprofitable growth-stage company.